Clinical Significance of PIK3CA Gene in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Table 1

Basic characteristics of included studies.

Author	Year	Country	Sample size	Positive, (%)	Histology type	Treatment	TNM stage	PIK3CA status	Outcome	Source of HR	NOS score
Endoh [16]	2006	Japan	52	26 (50)	NSCLC	Surg	I-IV	High expression	OS	R	6
Ludovini [17]	2011	Italy	145	6 (4.1)	NSCLC	Non-surg	III-IV	Mutation	OS/PFS	R	7
Zhang [18]	2013	China	122	24 (19.7)	AC	Surg	I-IV	Mutation	PFS	E	8
Iijima [19]	2014	China	57	45 (78.9)	SCC	Surg	I-III	High expression	OS	E	7
Toschi [20]	2014	Italy	435	127 (29.2)	NSCLC	Surg	I-IV	High expression	OS	E	7
Wang [21]	2014	China	1117	34 (3.0)	NSCLC	Surg	I-IV	Mutation	OS/PFS	E	7
Vieira [22]	2014	France	60	5 (8.3)	SMC	Surg	I-IV	Mutation	OS/PFS	R	7
McGowan [23]	2016	Norway	308	35 (11.4)	SCC	Surg	I-III	Mutation	OS	E	7
Song [24]	2016	China	810	23 (2.8)	AC	Surg	I-IIIA	Mutation	OS	R	8
Imperatori [25]	2017	Italy	167	5 (3.0)	NSCLC	Surg	I	Mutation	CSS	R	6
Wang [26]	2019	China	416	NR	NSCLC	Non-surg	III-IV	Mutation	OS/PFS	R	7
Chang [27]	2019	China	33	1 (3.0)	NSCLC	Non-surg	IV	Mutation	OS/PFS	R	7
Aredo [28]	2019	America	186	7 (3.8)	NSCLC	Mixed	NR	Mutation	OS	R	6

NSCLC: non-small-cell lung cancer; AC: adenocarcinoma; SCC: squamous cell carcinoma; SMC: sarcomatoid carcinoma; Surg: surgery; Non-surg: nonsurgery; TNM: tumor-node-metastasis; OS: overall survival; PFS: progression-free survival; CSS: cancer-specific survival; HR: hazard ratio; NR: not reported; R: reported; E: estimated; NOS: Newcastle-Ottawa quality assessment scale.